Management was focused on the reaction from the FDA and Big Pharma to Moffitt's poster at AACR, rather than the immediate attention (or lack thereof) of life sciences investors. Short interest for the period ending 3/28/13 fell 26%. I am traveling out of the country through the end of the week, and may blog sporadically until I return home.
No comments:
Post a Comment